Who are DTaP-HB PRP~T Combined Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, PCV10 and DTaP, Hualan TIV, immediate Cervarix, delayed MenVeo vaccine, Tetravalent Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dtap-hb-prp-t-combined-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

DTaP-HB PRP~T Combined Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DTaP-HB PRP~T Combined Vaccine (DTaP-HB PRP~T Combined Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology / Infectious Disease.

phase 3 Vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

DTaP-HB PRP~T Combined Vaccine (DTaP-HB PRP~T Combined Vaccine) — Sanofi Pasteur, a Sanofi Company. This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) by presenting inactivated toxins and bacterial antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DTaP-HB PRP~T Combined Vaccine TARGET	DTaP-HB PRP~T Combined Vaccine	Sanofi Pasteur, a Sanofi Company	phase 3	Vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
PCV10 and DTaP	PCV10 and DTaP	KEMRI-Wellcome Trust Collaborative Research Program	marketed	vaccine
Hualan TIV	Hualan TIV	Sanofi	marketed	Inactivated influenza vaccine
immediate Cervarix, delayed MenVeo vaccine	immediate Cervarix, delayed MenVeo vaccine	Massachusetts General Hospital	marketed	vaccine combination
Tetravalent Vaccine	Tetravalent Vaccine	Instituto Nacional de Salud Publica, Mexico	marketed	vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTaP-HB PRP~T Combined Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-hb-prp-t-combined-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab